Skip to main content

Insulet Corp(PODD-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low234.00
Day High239.97
Open:237.51
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Insulet Corp

Select a category then submit the form to load news
Tipranks
Insulet Finalizes Severance Terms for Departing CFO
StockStory
1 Oversold Stock Set for a Comeback and 2 Facing Challenges
SOUN
Tipranks
Insulet Earnings Call Highlights Growth And Expansion
Tipranks
Insulet (PODD) Gets a Buy from BTIG
Tipranks
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Charles River Labs (CRL) and Warby Parker (WRBY)
Tipranks
Analysts’ Top Healthcare Picks: CervoMed (CRVO), Insulet (PODD)
Tipranks
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Insulet (PODD)
Tipranks
Analysts’ Top Healthcare Picks: Charles River Labs (CRL), Harrow Health (HROW)
Tipranks
Truist Financial Sticks to Their Buy Rating for Insulet (PODD)
Tipranks
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Bausch Health Companies (BHC) and Insulet (PODD)
Tipranks
Goldman Sachs Sticks to Its Buy Rating for Insulet (PODD)
Tipranks
Analysts’ Top Healthcare Picks: Bausch + Lomb Corporation (BLCO), Insulet (PODD)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Bausch Health Companies (BHC) and Insulet (PODD)
Zacks Investment Research
PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise
PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise
Tipranks
Insulet Posts Strong Q4 Results, Expands Share Repurchase Program
StockStory
PODD Q4 Deep Dive: Type 2 Diabetes Expansion and Innovation Drive Outperformance
PODD
StockStory
Insulet (PODD) Shares Skyrocket, What You Need To Know
PODD
StockStory
Insulet (NASDAQ:PODD) Surprises With Q4 CY2025 Sales
PODD
StockStory
Earnings To Watch: Insulet (PODD) Reports Q4 Results Tomorrow
PODD
Newswire.ca
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
StockStory
3 Profitable Stocks for Long-Term Investors
CSW
StockStory
2 Cash-Producing Stocks with Impressive Fundamentals and 1 Facing Challenges
DV
Tipranks
BTIG Keeps Their Buy Rating on Insulet (PODD)
Tipranks
Analysts Conflicted on These Healthcare Names: Chugai Pharmaceutical Co (OtherCHGCF), Medtronic (MDT) and Insulet (PODD)
Tipranks
Insulet Extends Key Supply Agreement with NXP USA
StockStory
2 S&P 500 Stocks to Research Further and 1 Facing Challenges
AMAT
Tipranks
Insulet’s Omnipod M Study Completes Key Milestone in Type 2 Diabetes Onboarding
Tipranks
Insulet Completes Key Omnipod 5 SmartAdjust 2.0 Study, Setting Up Next Growth Phase
Tipranks
Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Gilead Sciences (GILD)
StockStory
1 Safe-and-Steady Stock with Impressive Fundamentals and 2 We Find Risky
WMT
Motley Fool
Is Insulet (PODD) the Future of Diabetes Management?
Tipranks
Insulet (PODD) Receives a Buy from Bernstein

Profile

Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.